Emedgene

AI-based Platform for Automated Genomic Interpretation

Health Tech & Life Sciences
Acquired by Illumina
Acquired Tel Aviv-Yafo, Israel Founded 2015
LinkedIn
Last updated 2026-06-18
Total raised
$6.0M
Last: 2019-02
Stage
Acquired
Founded
2015
Headcount
32
HQ
Tel Aviv-Yafo, Israel
Sector
Health Tech & Life Sciences

About

Emedgene is a genomics intelligence platform that uses natural language processing to digest new genetic publications and incorporate them into an always-up-to-date knowledge base. It then runs machine-learning discovery algorithms to pinpoint pathogenic variants for a clear path to clinical decisions. Clinical labs using Emedgene can improve dry lab efficiency, reduce time spent on interpretation and reporting, increase yield, and scale up their genomic interpretation operation. Research organizations using Emedgene can accelerate genomic-driven discovery through the application of end-to-end artificial intelligence, from natural language processing of publications through custom machine-learning algorithms. Emedgene aims to help geneticists and clinicians understand the clinical meaning of unique genetic variants so that they can provide their patients with personalized care.

Funding history · 3 rounds · $6.0M total

2018-10
2017-08
Undisclosed

Q&A

What is Emedgene's primary business?
Emedgene is a genomics intelligence platform that uses natural language processing and machine learning to interpret genetic publications and pinpoint pathogenic variants for clinical decisions.
When was Emedgene founded?
Emedgene was founded in April 2015.
What is the current status of Emedgene?
Emedgene was acquired by Illumina in December 2021 and is currently inactive.
How much funding has Emedgene raised in total?
Emedgene has raised a total of $6,019,000 across its funding rounds.
When was Emedgene's last funding round and who were the lead investors?
Emedgene's last funding round occurred in February 2019, with OTV as a lead investor.
Who are the co-founders of Emedgene?
The co-founders of Emedgene are Einat Metzer (CEO), Shay Tzur (CSO), and Niv Mizrahi (CTO).
What technologies does Emedgene utilize in its platform?
Emedgene utilizes Artificial Intelligence, Machine Learning, and Natural Language Processing in its platform.

Team · 3

Founder · Co-Founder & CEO
LinkedIn ↗
Founder · Co-founder & CSO
LinkedIn ↗
Founder · Co-founder & CTO
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesDigital HealthcareMedical Decision Support
Technologies
BiologicalsGenesArtificial IntelligenceMachine LearningNatural Language Processing
Target customers
EducationHigher EducationHealthcare & Life SciencesHealthcareLaboratoriesProviders
Business model
B2B

Highlights

Verified

Tags

big-datagenomicsmedical-technologiesartificial-intelligencehealthcare-providersprecision-medicinegeneticsmachine-learninghospitalslaboratoriesdoctorsdeep-learningnatural-language-processingdiagnosticsdigital-healthcaredata-analyticspersonalized-medicinetreatmentsgenetic-disordersdecision-supportsaasacademia
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)